Cytokine production in patients with cirrhosis and TLR4 polymorphisms

Table 1 Clinical and analytical characteristics of patients with TLR4 polymorphisms and wild-type patients n (%)

	Polymorphisms (n = 9)	Wild-type (n = 10)	P value
Age (yr)	63.2 (40-78)	61.0 (42-79)	0.93
Sex (male/female)	6 (67)/3 (33)	6 (60)/4 (40)	1.00
Etiology (alcohol/HCV/alcohol + HCV/other)	3 (33)/3 (33)/2 (22)/1 (11)	5 (50)/2 (20)/3 (30)/0 (0)	0.5
Child-Pugh score	7 (5-9)	6 (5-8)	0.49
MELD score	11 (6-16)	12 (6-18)	0.62
Serum bilirubin (μmol/L)	17.0 (7-41)	27.5 (9-60)	0.56
Serum albumin (g/L)	32.8 (22.7-49.4)	35.9 (30.0-43.9)	0.34
INR	1.10 (1.01-1.48)	1.22 (0.96-1.39)	0.68
Blood total leukocyte count (× 109/L)	5.89 (2.75-11.48)	5.67 (3.84-8.57)	0.93
Blood neutrophil count (× 109/L)	3.30 (2.00-7.78)	3.21 (1.61-5.63)	0.74
Blood monocyte count (× 109/L)	0.59 (0.20-0.98)	0.66 (0.38-1.00)	0.46
Blood lymphocyte count (× 109/L)	1.00 (0.38-2.15)	1.41 (0.35-2.22)	0.39
Present ascites	3 (33)	3 (30)	1.00
Diuretics	6 (67)	9 (90)	0.30
Beta-blockers	4 (44)	5 (50)	1.00
Norfloxacin prophylaxis	5 (55)	4 (40)	0.65

HCV: Hepatitis C virus; MELD: Model for end-stage liver disease; INR: International normalized ratio.